MD, Chief Physician. Currently serves as the Director of the Department of Interventional Therapy, Inner Mongolia Hospital of Peking University Cancer Hospital. Specialties: Image‑guided minimally invasive interventional therapy for tumors, including transarterial chemoembolization, ablation, radioactive seed implantation for malignant tumors such as primary liver cancer, metastatic liver cancer and lung cancer, as well as interventional therapy for tumor‑related complications.
Research Projects:
- Special Clinical Research Fund of Peking University Cancer Hospital, Randomized Controlled Study of Bevacizumab Combined with Irinotecan‑eluting Embolic Agents for Liver Metastases from Colorectal Cancer, 2021/12‑2024/11, 100,000 RMB, Principal Investigator;
- General Program of National Natural Science Foundation of China, Grant No. 81571781, Study on the Molecular Mechanism and Clinical Value of FOXB2 and DBX2 in the Oncogenesis and Progression of Primary Hepatocellular Carcinoma, 2017/05‑2020/06, 500,000 RMB, Participant;
- Capital Health Development Research Special Fund (Independent Innovation Project), Grant No. Shoufa 2014‑2‑2154, Randomized Controlled Study of Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil after TACE for Advanced Primary Liver Cancer, 2014/09‑2017/12, 400,000 RMB, Project Completed, Major Participant;
- Sub‑project of the National Major Project for the 12th Five‑Year Plan, Grant No. 2012ZX10002015‑003, Phase IV Clinical Study of Licartin Combined with TACE in the Treatment of Primary Liver Cancer, 2017/05‑2020/06, 500,000 RMB, Participant.
English